Once-Weekly Semaglutide in Adults with Overweight or Obesity – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
This double-blind study randomly assigned adults with obesity without diabetes to 68 weeks of once-weekly subcutaneous semaglutide or placebo, plus lifestyle intervention. Semaglutide therapy was associated with sustained, clinically relevant weight reduction.
— NEJM (@NEJM) February 10, 2021